凯发一触即发

至今,GenScript的服务及产品已被Cell, Nature, Science, PNAS等1300多家生物医药类杂志引用近万次,处于行业领先水平。NIH、哈佛、耶鲁、斯坦福、普林斯顿、杜克大学等约400家全球著名机构使用GenScript的基因合成、多肽服务、抗体服务和蛋白服务等成功地发表科研成果,再次证明GenScript 有能力帮助业内科学家Make research easy.

Intraocular Penetration of a vNAR: In Vivo and In Vitro VEGF Neutralization.

Mar Drugs. 2018; 
Camacho-VillegasTanya A,Mata-GonzálezMaría Teresa,García-UbbelohdWalter,Núñez-GarcíaLinda,ElosuaCarolina,Paniagua-SolisJorge F,Licea-NavarroAlex
Products/Services Used Details Operation
Anti-HA tag secondary antibody (Genscript (Piscataway, NJ, USA), A01244-100) was diluted in wash buffer to 50 ng/mL and incubated for 1.5 h in RT (100 µL/well).

摘要

Variable new antigen receptor domain (vNAR) antibodies are novel, naturally occurring antibodies that can be isolated from naïve, immune or synthetic shark libraries. These molecules are very interesting to the biotechnology and pharmaceutical industries because of their unique characteristics related to size and tissue penetrability. There have been some approved anti-angiogenic therapies for ophthalmic conditions, not related to vNAR. This includes biologics and chimeric proteins that neutralize vascular endothelial growth factor (VEGF), which are injected intravitreal, causing discomfort and increasing the possibility of infection. In this paper, we present a vNAR antibody against human recombin... More

关键词

Heterodontus fransisci,VEGF165,age-related macular degeneration,diabetic retinopathy,horn shark,intraocular penetration,single chain binding domain,